Compounds > lovastatin
Page last updated: 2024-08-23

lovastatin and Autosomal Dominant Juvenile Parkinson Disease

lovastatin has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80

Authors

AuthorsStudies
Guo, W; Liu, B; Liu, W; Ma, H; Ouyang, L; Shen, L; Sun, Y; Wang, M; Xu, Q; Zhu, Y1
Huang, WJ; Lee, MH; Lin, CM; Lin, RD; Lin, YT1
Aguirre-Vidal, Y; Anaya-Ramos, L; Baron-Flores, V; Monroy-Noyola, A; Montes, S; Ríos, C; Teiber, J; Tristan-López, L1
Cao, LP; Chen, ML; Chien, CT; Farrer, MJ; Lai, TT; Lin, CH; Lin, HI; Wu, RM1
Müller, T1

Other Studies

5 other study(ies) available for lovastatin and Autosomal Dominant Juvenile Parkinson Disease

ArticleYear
SHP2-mediated mitophagy boosted by lovastatin in neuronal cells alleviates parkinsonism in mice.
    Signal transduction and targeted therapy, 2021, 01-29, Volume: 6, Issue:1

    Topics: Animals; Humans; Lovastatin; Mice; Mitophagy; Molecular Docking Simulation; Neurons; Parkinsonian Disorders; Protein Tyrosine Phosphatase, Non-Receptor Type 11

2021
Neurocytoprotective Effects of Aliphatic Hydroxamates from Lovastatin, a Secondary Metabolite from Monascus-Fermented Red Mold Rice, in 6-Hydroxydopamine (6-OHDA)-Treated Nerve Growth Factor (NGF)-Differentiated PC12 Cells.
    ACS chemical neuroscience, 2015, May-20, Volume: 6, Issue:5

    Topics: Animals; Apoptosis; Cell Differentiation; Cell Survival; Lovastatin; Models, Biological; Monascus; Nerve Growth Factor; Neurons; Neuroprotective Agents; Oryza; Oxidopamine; Parkinsonian Disorders; PC12 Cells; Rats

2015
The neuroprotective effect of lovastatin on MPP(+)-induced neurotoxicity is not mediated by PON2.
    Neurotoxicology, 2015, Volume: 48

    Topics: 1-Methyl-4-phenylpyridinium; Animals; Aryldialkylphosphatase; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Lipid Peroxidation; Lipid Peroxides; Lovastatin; Male; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Rats, Wistar; Signal Transduction

2015
Lovastatin protects neurite degeneration in LRRK2-G2019S parkinsonism through activating the Akt/Nrf pathway and inhibiting GSK3β activity.
    Human molecular genetics, 2016, 05-15, Volume: 25, Issue:10

    Topics: Animals; Animals, Genetically Modified; Dopaminergic Neurons; Drosophila melanogaster; Glycogen Synthase Kinase 3 beta; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Lovastatin; Mice; Motor Neurons; Mutation; Nerve Degeneration; Neurites; Parkinson Disease; Parkinsonian Disorders; Proto-Oncogene Proteins c-akt; Serine Endopeptidases; Signal Transduction

2016
[Statin-induced Parkinson's-syndrome. Reader's letter on the article by J. Finsterer in "Der Nervenarzt" (2003) 74:115-122].
    Der Nervenarzt, 2003, Volume: 74, Issue:8

    Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Muscular Diseases; Parkinsonian Disorders; Rhabdomyolysis

2003